Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus

Björk, Mathilda; Dahlström, Örjan; Wetterö, Jonas; Sjöwall, Christopher

doi:10.1186/s12891-015-0621-3

Cited by 50 publications

(47 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Function as measured by mHAQ was influenced strongly by disease activity, but not by damage. Other studies showed a correlation of HAQ (Health Assessment Questionnaire) with both SLEDAI and SDI [31, 32]. In our study a relationship between health statuses measured by mHAQ was not significantly correlated to damage, possibly due to the limited size of our cohort and also since mHAQ was used, as opposed to HAQ.…”

Section: Resultscontrasting

confidence: 72%

Characterisation of Patients with Systemic Lupus Erythematosus in Malta: A Population Based Cohort Cross-Sectional Study

Magro

Borg

2018

BioMed Research International

View full text Add to dashboard Cite

Systemic Lupus Erythematosus (SLE) is a multisystemic autoimmune disorder. The aim of this study was to characterise the SLE patients living in Malta in order to estimate the prevalence and incidence of SLE and characterise the clinical presentation as well as identify any unmet needs. 107 SLE patients who fulfilled SLICC classification criteria were identified. These were invited to participate in the study by means of an interview, blood and urine tests, and filling of the following questionnaires: Fatigue Severity Scale (FSS), visual analogue scale (VAS) for fatigue, Hospital Anxiety and Depression Scale (HADS), VAS for pain, Pittsburgh Sleep Quality Index (PSQI), and modified Health Assessment Questionnaire (mHAQ). The estimated prevalence of SLE in Malta is 29.3 patients per 100,000 and the estimated incidence is 1.48 per 100,000 per year. 93.5% of SLE patients were female, and the mean age at diagnosis was 33.1 years. 60.8% were overweight or obese and body mass index (BMI) had a significant positive correlation with daily dose of prednisolone (R=0.177, p=0.046). 20.7% and 3.3% had a moderate and high disease activity, respectively, as measured by SLEDAI-2K. Disease activity had a significant positive correlation with functional disability measured by mHAQ (R=0.417, p<0.001). 56.5% had an abnormal level of fatigue (FSS >3.7) and 57.6% had a high level of anxiety (HADS ≥8). This study has identified a number of unmet needs of SLE patients, including obesity, uncontrolled disease activity, fatigue, and anxiety.

show abstract

Section: Resultscontrasting

confidence: 72%

Characterisation of Patients with Systemic Lupus Erythematosus in Malta: A Population Based Cohort Cross-Sectional Study

Magro

Borg

2018

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…In summary, SOC worked, but did not lead to remission in all patients. As expected from personal contact and from the literature [ 9 , 10 ], the majority of patients reported problems with paid work, social life and leisure activities including traveling (Fig. 2 ).…”

Section: Resultssupporting

confidence: 72%

The patients’ perspective: living with lupus in Austria

Stummvoll

Stamm

2017

Wien Klin Wochenschr

View full text Add to dashboard Cite

SummarySystemic lupus erythematosus (SLE) is a heterogeneous disease with a vast variety of clinical manifestations. Timely diagnosis is important for gaining access to specific therapy and care. In this survey, we asked SLE patients with an established diagnosis to report about their personal history and their daily life with SLE in order to gain knowledge about diagnostics, treatment pathways and potential problems in daily living and functioning. In most cases, the diagnosis of SLE was made by a specialist in rheumatology or dermatology. Of the patients 41.5% were diagnosed within the first year after onset of disease symptoms, while 37.3% of the patients waited for 3 or more years for the final diagnosis of SLE. Interestingly, we found no differences with respect to patients living in urban or rural areas. Specific therapy worked well in many but not in all patients: the majority of patients reported problems with paid work, social life and leisure activities including traveling. Patients reported a need for better information for the general public about SLE. In addition, they wanted be better informed themselves. Despite all successful efforts in recent years, there is still room for improvement with respect to early diagnosis, early start of specific therapy and for better information of the public on the mysterious disorder named SLE.

show abstract

“…SLE is a complex autoimmune multisystemic disease, with a huge impact on quality of life and development of organ damage [ 34 , 35 ]. Despite having a large number of studies clarify many aspects of the pathogenesis of this disease, a comprehensive understanding of the immunological phenomena underlying the clinical manifestations of SLE still remains a challenge [ 36 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results

Navarini

Bisogno

Margiotta

et al. 2018

Journal of Immunology Research

View full text Add to dashboard Cite

Objective Systemic lupus erythematosus (SLE) is an autoimmune systemic disease and its pathogenesis has not yet been completely clarified. Patients with SLE show a deranged lipid metabolism, which can contribute to the immunopathogenesis of the disease and to the accelerated atherosclerosis. Resolvin D1 (RvD1), a product of the metabolism of the omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA), acts as a specialized proresolving mediator which can contribute in restoring the homeostasis in inflamed tissues. The aim of the present pilot study is to evaluate plasma levels of RvD1 in patients with SLE and healthy subjects, investigating its potential role as a biomarker of SLE and assessing its relationship with disease activity and laboratory parameters. Methods Thirty patients with SLE and thirty age- and sex-matched healthy subjects (HSs) have been consecutively recruited at Campus Bio-Medico University Hospital. RvD1 plasma levels were measured by ELISA according to the manufacturer's protocol (Cayman Chemical Co.). RvD1 levels were compared using Mann–Whitney test. Discriminatory ability for SLE has been evaluated by the area under the ROC curve. Results Lower levels of RvD1, 45.6 (35.5–57.4) pg/ml, in patients with SLE have been found compared to HSs, 65.1 (39.43–87.95) pg/ml (p = 0.0043). The area under the ROC curve (AUC) for RvD1 was 0.71 (95% CI: 0.578–0.82) and the threshold value of RvD1 for the classification of SLE was <58.4 pg/ml, sensitivity 80% (95% CI: 61.4–92.3), and specificity 63.3% (95% CI: 43.9–80.1), likelihood ratio 2.2 (95% CI: 1.3–3.6). Conclusions The present preliminary study allows hypothesizing a dysregulation of RvD1 in patients with SLE, confirming the emerging role of bioactive lipids in this disease.

show abstract

Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus

Cited by 50 publications

References 47 publications

Characterisation of Patients with Systemic Lupus Erythematosus in Malta: A Population Based Cohort Cross-Sectional Study

Characterisation of Patients with Systemic Lupus Erythematosus in Malta: A Population Based Cohort Cross-Sectional Study

The patients’ perspective: living with lupus in Austria

Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results

Contact Info

Product

Resources

About